Sanuwave Health, a provider of FDA-approved wound care products, refinanced its $27.5 million debt facility with NH Expansion Credit Fund with a new secured credit facility from J.P. Morgan consisting of a $23 million term loan, which amortizes over four years, and a two-year $5 million receivables backed revolving credit facility, from which the company drew approximately $1 million at closing. Both facilities have an interest rate of SOFR (Secured Overnight Financing Rate) +350bp and neither facility has any prepayment penalties.
The use of proceeds for the $24 million borrowing at closing was the partial repayment of the NH Expansion debt facility. The remaining $3.5 million owed on the NH Expansion debt facility and additional transaction and initiation costs (including costs to close out the NH Expansion debt facility) of approximately $1.3 million were repaid using cash accumulated from the company’s operations and from its sale of certain intravascular shockwave patents disclosed in the company’s current report on 8-K filed on Aug. 21, 2025.
“This refinancing marks a pivotal step in strengthening Sanuwave’s financial position,” Morgan Frank, CEO of Sanuwave, said. “The significant reduction in our interest rate, the reduction of our overall debt load, and a move to a set of ‘no prepayment penalty’ terms all position us to better generate cash flow in support of our ongoing mission to pay down our debt out of operating cash flow. We could not ask for a better lender than J.P. Morgan, whose reputation for global leadership in banking needs no introduction. They have already been a great help, and we look forward to working with them going forward.”
